# Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)

> **NCT00289549** · PHASE2 · COMPLETED · sponsor: **BioCryst Pharmaceuticals** · enrollment: 8 (actual)

## Conditions studied

- Leukemia, Lymphocytic, Chronic

## Interventions

- **DRUG:** forodesine hydrochloride (BCX-1777)

## Key facts

- **NCT ID:** NCT00289549
- **Lead sponsor:** BioCryst Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2012-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00289549

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00289549, "Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00289549. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*